ArticleNPJ breast cancer2019
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- An exosome-related gene signature predicts prognosis, immune suppression, and therapeutic sensitivity in luminal breast cancer.Discover oncology · 2026Article
- Clinicogenomic Landscape and Function ofJCO precision oncology · 2026Article
- ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer.British journal of cancer · 2026Article
- Regulators of homologous recombination deficiency identified by machine learning using somatic multi-omics data.Life science alliance · 2026Article
- FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer.Frontiers in immunology · 2025Article
- Breast cancer genomic analyses reveal genes, mutations, and signaling networks.Functional & integrative genomics · 2024Article
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- HTRA1 expression is associated with immune-cell infiltration and survival in breast cancer.Translational cancer research · 2023Article
- Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer.Scientific reports · 2023Article
- Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer.International journal of molecular sciences · 2023Review
- Integrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer.iScience · 2023Article
- Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.Breast cancer research : BCR · 2023Article
- N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.Cell reports. Medicine · 2023Article
- Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Article
- ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain.Cell reports · 2022Article
- Review
- PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer.NPJ breast cancer · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 1 country.
Funding
Abstract
Clinical trials have demonstrated the efficacy of combining phosphoinositide 3-kinase (PI3K) inhibitors with endocrine therapies in hormone therapy-refractory breast cancer. However, biomarkers of PI3K pathway dependence in ER+ breast cancer have not been fully established. Hotspot mutations in the alpha isoform of PI3K (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.